BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Masana L, Correig E, Rodríguez-Borjabad C, Anoro E, Arroyo JA, Jericó C, Pedragosa A, Miret M, Näf S, Pardo A, Perea V, Pérez-Bernalte R, Plana N, Ramírez-Montesinos R, Royuela M, Soler C, Urquizu-Padilla M, Zamora A, Pedro-Botet J, Group OBOTSR. EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED. Eur Heart J Cardiovasc Pharmacother 2020:pvaa128. [PMID: 33135047 DOI: 10.1093/ehjcvp/pvaa128] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Kow CS, Hasan SS. The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. Am J Cardiovasc Drugs 2022;22:167-81. [PMID: 34341972 DOI: 10.1007/s40256-021-00490-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Louie AY, Tingling J, Dray E, Hussain J, McKim DB, Swanson KS, Steelman AJ. Dietary Cholesterol Causes Inflammatory Imbalance and Exacerbates Morbidity in Mice Infected with Influenza A Virus. J Immunol 2022;208:2523-39. [PMID: 35577367 DOI: 10.4049/jimmunol.2100927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Vuorio A, Strandberg TE, Raal F, Santos RD, Kovanen PT. Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. Atheroscler Plus 2021;43:3-6. [PMID: 34622243 DOI: 10.1016/j.athplu.2021.08.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Orlowski S, Mourad JJ, Gallo A, Bruckert E. Coronaviruses, cholesterol and statins: Involvement and application for Covid-19. Biochimie 2021;189:51-64. [PMID: 34153377 DOI: 10.1016/j.biochi.2021.06.005] [Reference Citation Analysis]
5 Hariyanto TI, Kurniawan A. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. Nutr Metab Cardiovasc Dis 2021;31:1662-70. [PMID: 33838992 DOI: 10.1016/j.numecd.2021.02.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
6 Lohia P, Kapur S, Benjaram S, Cantor Z, Mahabadi N, Mir T, Badr MS. Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. Cardiovasc Diabetol 2021;20:140. [PMID: 34246277 DOI: 10.1186/s12933-021-01336-0] [Reference Citation Analysis]
7 Shen Y, Chen D, Huang X, Cai G, Xu Q, Hu C, Yan J, Liu J. Novel phenotypes of coronavirus disease: a temperature-based trajectory model. Ann Intensive Care 2021;11:121. [PMID: 34342755 DOI: 10.1186/s13613-021-00907-4] [Reference Citation Analysis]
8 Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca Á, Saravia-Bartra MM, Cazorla P, Belzusarri I, Hernandez AV. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients. Int J Infect Dis 2021;110:374-81. [PMID: 34375760 DOI: 10.1016/j.ijid.2021.08.004] [Reference Citation Analysis]
9 Alves M, Fernandes MA, Bahat G, Benetos A, Clemente H, Grodzicki T, Martínez-Sellés M, Mattace-Raso F, Rajkumar C, Ungar A, Werner N, Strandberg TE; EuGMS Special Interest Group inCardiovascular Medicine (Chairpersons A. Ungar and A. Benetos). Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications. Eur Geriatr Med 2021;12:725-39. [PMID: 34031865 DOI: 10.1007/s41999-021-00504-5] [Reference Citation Analysis]
10 Marquès M, Correig E, Ibarretxe D, Anoro E, Antonio Arroyo J, Jericó C, Borrallo RM, Miret M, Näf S, Pardo A, Perea V, Pérez-Bernalte R, Ramírez-Montesinos R, Royuela M, Soler C, Urquizu-Padilla M, Zamora A, Pedro-Botet J, Masana L, Domingo JL; STACOV-XULA research group. Long-term exposure to PM10 above WHO guidelines exacerbates COVID-19 severity and mortality. Environ Int 2021;158:106930. [PMID: 34678637 DOI: 10.1016/j.envint.2021.106930] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
11 Byttebier G, Belmans L, Alexander M, Saxberg BEH, De Spiegeleer B, De Spiegeleer A, Devreker N, Van Praet JT, Vanhove K, Reybrouck R, Wynendaele E, Fedson DS. Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. Hum Vaccin Immunother 2021;17:2841-50. [PMID: 34047686 DOI: 10.1080/21645515.2021.1920271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Shen T, Wang T. Metabolic Reprogramming in COVID-19. Int J Mol Sci 2021;22:11475. [PMID: 34768906 DOI: 10.3390/ijms222111475] [Reference Citation Analysis]
13 Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metab 2021;33:479-98. [PMID: 33529600 DOI: 10.1016/j.cmet.2021.01.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 30.0] [Reference Citation Analysis]
14 Yetmar ZA, Challener DW, Tleyjeh IM, Sohail MR, Cerhan JR, Badley AD, O'Horo JC. Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19. Mayo Clin Proc Innov Qual Outcomes 2021;5:442-6. [PMID: 33748678 DOI: 10.1016/j.mayocpiqo.2021.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Martin JH, Baddeley M, Head R. Did our pharmacological strategy for COVID-19 fail? Pharmacol Res Perspect 2021;9:e00866. [PMID: 34708568 DOI: 10.1002/prp2.866] [Reference Citation Analysis]
16 Pal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad Med J 2021:postgradmedj-2020-139172. [PMID: 33541927 DOI: 10.1136/postgradmedj-2020-139172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
17 Vuorio A, Kovanen PT. Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond. Front Pharmacol 2020;11:579548. [PMID: 33542685 DOI: 10.3389/fphar.2020.579548] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
18 Oz M, Lorke DE, Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. Pharmacol Ther 2021;221:107750. [PMID: 33275999 DOI: 10.1016/j.pharmthera.2020.107750] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Kouhpeikar H, Khosaravizade Tabasi H, Khazir Z, Naghipour A, Mohammadi Moghadam H, Forouzanfar H, Abbasifard M, Kirichenko TV, Reiner Ž, Banach M, Sahebkar A. Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. Front Cardiovasc Med 2022;9:820260. [DOI: 10.3389/fcvm.2022.820260] [Reference Citation Analysis]
20 Zapatero-Belinchón FJ, Moeller R, Lasswitz L, van Ham M, Becker M, Brogden G, Rosendal E, Bi W, Carriquí-Madroñal B, Islam K, Lenman A, Gunesch AP, Kirui J, Pietschmann T, Överby AK, Jänsch L, Gerold G. Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience 2021;24:103469. [PMID: 34812415 DOI: 10.1016/j.isci.2021.103469] [Reference Citation Analysis]
21 Hussain M, Khurram Syed S, Fatima M, Shaukat S, Saadullah M, Alqahtani AM, Alqahtani T, Bin Emran T, Alamri AH, Barkat MQ, Wu X. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. J Inflamm Res 2021;14:7225-42. [PMID: 34992415 DOI: 10.2147/JIR.S334043] [Reference Citation Analysis]
22 Kollias A, Kyriakoulis KG, Kyriakoulis IG, Nitsotolis T, Poulakou G, Stergiou GS, Syrigos K. Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis 2021;330:114-21. [PMID: 34243953 DOI: 10.1016/j.atherosclerosis.2021.06.911] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Masana L, Correig E, Ibarretxe D, Anoro E, Arroyo JA, Jericó C, Guerrero C, Miret M, Näf S, Pardo A, Perea V, Pérez-Bernalte R, Plana N, Ramírez-Montesinos R, Royuela M, Soler C, Urquizu-Padilla M, Zamora A, Pedro-Botet J; STACOV-XULA research group. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep 2021;11:7217. [PMID: 33785815 DOI: 10.1038/s41598-021-86747-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
24 Lee WS, Yousefi M, Yan B, Yong CL, Ooi YS. Know your enemy and know yourself - the case of SARS-CoV-2 host factors. Curr Opin Virol 2021;50:159-70. [PMID: 34488003 DOI: 10.1016/j.coviro.2021.08.007] [Reference Citation Analysis]
25 Vahedian-Azimi A, Mohammadi SM, Heidari Beni F, Banach M, Guest PC, Jamialahmadi T, Sahebkar A. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch Med Sci 2021;17:579-95. [PMID: 34025827 DOI: 10.5114/aoms/132950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Mormile R. Il-6, Il-1β and cytokine-targeted therapy for COVID -19 patients: two more reasons to take into account statins? Expert Rev Cardiovasc Ther 2022;:1-3. [PMID: 35323082 DOI: 10.1080/14779072.2022.2058490] [Reference Citation Analysis]
27 Scicali R, Piro S, Ferrara V, Di Mauro S, Filippello A, Scamporrino A, Romano M, Purrello F, Di Pino A. Direct and Indirect Effects of SARS-CoV-2 Pandemic in Subjects with Familial Hypercholesterolemia: A Single Lipid-Center Real-World Evaluation. J Clin Med 2021;10:4363. [PMID: 34640388 DOI: 10.3390/jcm10194363] [Reference Citation Analysis]
28 Vuorio A, Lassila R, Kovanen PT. Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism. Front Cardiovasc Med 2021;8:711923. [PMID: 34722654 DOI: 10.3389/fcvm.2021.711923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wander PL, Lowy E, Beste LA, Tulloch-Palomino L, Korpak A, Peterson AC, Kahn SE, Danaei G, Boyko EJ. Associations of statin use with 30-day adverse outcomes among 4 801 406 US Veterans with and without SARS-CoV-2: an observational cohort study. BMJ Open 2022;12:e058363. [PMID: 35304400 DOI: 10.1136/bmjopen-2021-058363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wu CC, Lee AJ, Su CH, Huang CY, Islam MM, Weng YC. Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19. J Clin Med 2021;10:1450. [PMID: 33916281 DOI: 10.3390/jcm10071450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Vahedian-Azimi A, Mohammadi SM, Banach M, Beni FH, Guest PC, Al-Rasadi K, Jamialahmadi T, Sahebkar A. Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. Biomed Res Int 2021;2021:1901772. [PMID: 34568488 DOI: 10.1155/2021/1901772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Scheen AJ. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes Metab 2020;47:101220. [PMID: 33359486 DOI: 10.1016/j.diabet.2020.101220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rahimibashar F, Sedighi L, Shahriary A, Reiner Z, Pourhoseingholi MA, Mirmomeni G, Jouzdani AF, Vahedian-Azimi A, Jamialahmadi T, Sahebkar A. Is there any association between plasma lipid profile and severity of COVID-19? Clin Nutr ESPEN 2022;49:191-6. [PMID: 35623812 DOI: 10.1016/j.clnesp.2022.04.026] [Reference Citation Analysis]